Erasca Announces Merck Collaboration for ERAS-0015, Reports Strong Cash Position and Q1 Results
ERAS has more than doubled off its 52-week low of $1.06.
Summary
Erasca announced a new clinical collaboration with Merck for its lead asset ERAS-0015, alongside reporting a strong cash position of $408.5 million with an extended runway into H2 2028, and Q1 2026 financial results.
Key Events · M&A and Partnerships · ERAS
-
New Clinical Collaboration with Merck
Erasca entered a Clinical Trial Collaboration and Supply Agreement with Merck to evaluate ERAS-0015 in combination with KEYTRUDA® (pembrolizumab). Merck will supply pembrolizumab at no cost, with Erasca as the trial sponsor.
-
Strong Cash Position and Runway
Reported $408.5 million in cash, cash equivalents, and marketable securities as of March 31, 2026, extending its cash runway into the second half of 2028.
-
ERAS-4001 Patent Issued
A U.S. composition of matter patent was issued for ERAS-4001, protecting the pan-KRAS inhibitor until June 2043.
-
ERAS-0015 Clinical Advancement Ahead of Schedule
Monotherapy expansion and combination dose escalation cohorts for ERAS-0015 were initiated ahead of the original second half of 2026 guidance.
Analysis · ERAS · Life Sciences
This filing is important due to the new clinical collaboration with Merck, which validates Erasca's lead asset, ERAS-0015, and provides resources for its development. The confirmation of a robust cash position and extended runway into H2 2028 is crucial for a clinical-stage biotech, de-risking its operations. While the net loss increased significantly, it is primarily attributable to a strategic investment in expanding worldwide rights for ERAS-0015, a positive long-term move. The patent for ERAS-4001 further strengthens the company's intellectual property.
At the time of this filing, ERAS was trading at $10.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.2B. The 52-week trading range was $1.06 to $24.28. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.